Both established and rarer liver diseases – including cirrhosis, alcoholic-associated liver disease, metabolic-dysfunction associated steatohepatitis (MASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) – present complex management challenges requiring sophisticated clinical insight. With evolving treatment options and increasing disease prevalence, robust real-world evidence is essential for understanding disease progression, guiding therapeutic strategies, securing reimbursement, and building confidence across healthcare systems.
Adelphi Real World’s Liver Disease Specific Programmes (DSPs) are designed to meet these challenges.
Our Liver DSPs engage practising specialists (hepatologists, gastroenterologists, endocrinologists) as well as primary care physicians and patients to deliver real-world insights that inform clinical and commercial decisions:
Disease Assessment & Monitoring
Understand how healthcare practitioners diagnose, stage, and monitor liver disease – capturing assessment methodologies, biomarker utilisation, and disease severity approaches in routine clinical practice.
Treatment Strategies & Management Patterns
Explore and understand real-world treatment practices across the liver disease space, including, therapy selection, sequencing, comorbidity assessment and management/co-management with other HCPs, treatment of symptoms.
Clinical Outcomes & Disease Progression
Track real-world effectiveness and level of satisfaction: liver-related outcomes, disease stabilisation, transplant-free survival, and functional improvement across diverse patient populations and healthcare settings.
Patient Impact & Burden
Explore disease burden: symptom severity, complications, functional limitations, impact on work and activity, and quality-of-life consequences for liver disease patients.
Therapeutic Gaps & Unmet Needs
Identify opportunities for innovation, areas where current management falls short, and treatment challenges that require new therapeutic approaches.
Liver Disease Specific Programmes (DSPs) Portfolio
Click on the hexagons to expand.
Why Partner With Adelphi?
Hepatology Expertise
Deep specialisation in liver disease across multiple aetiologies.
Comprehensive Condition Coverage
Evidence spanning fibrotic, autoimmune, and metabolic liver diseases.
Patient-Informed Intelligence
Evidence centred on patient experience and disease impact.
Methodological Rigour
Quantitative benchmarking combined with qualitative clinical depth.
Strategic Insights
Evidence supporting development, market access, and stakeholder engagement.
Geographies Covered By DSPs In Liver Diseases
Who We Partner With
We partner with a wide range of organisations to advance liver disease research and improve patient outcomes globally.
Ready to Explore?
- Schedule a Consultation: Connect with us to discuss how our real-world evidence supports your liver programmes.
- Learn More: Curious about our global coverage, condition focus, or data approach? Contact us for detailed information.
Liver diseases require research partners with expertise in liver disease and practitioner networks. Adelphi Real World delivers specialist knowledge, practitioner access, and rigorous methodology. Let’s partner to generate evidence that drives innovation and better patient outcomes.
Contact us today using the form below.
Conferences Attending
Observational Research